Differentiated Brands,
Unique Profiles,
Patient-Focused
Commercial Products
Our product portfolio includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) oral solution, a prescription laxative for the treatment of constipation;
- Sancuso® (granisetron) transdermal for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Marketed
Acetadote®
Acetadote® (acetylcysteine) is our IV treatment of liver toxicity associated with acetaminophen overdose, the leading cause of drug toxicity in the U.S. It was developed by Cumberland and was the first injectable product available to treat acetaminophen overdose available in this country. Though safe at recommended doses, acetaminophen can cause liver damage with excessive use.
Acetadote is used in the emergency department, the intensive care unit, and hospital inpatient settings to prevent or lessen liver damage from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription medications. Acetadote is FDA-approved for adult and pediatric use. It is free of EDTA as well as any other stabilizing, chelating, or preserving chemicals and has become a standard of care for the treatment of this potentially life-threatening condition.
For more information, including full prescribing and important safety data, visit:
Marketed
Caldolor®
Caldolor® (ibuprofen) was the first injectable therapy approved in the United States for the treatment of both pain and fever. It is indicated in adult and pediatric (newborn) patients as a sole treatment for the management of mild to moderate pain; as an adjunct to reduce the use of opioids in the management of moderate to severe pain; and for the reduction of fever.
Caldolor provides distinct benefits to physicians treating post-operative pain. In addition to working peripherally at the site of trauma, it also acts centrally to blunt the perception of pain. Clinical trials have shown that Caldolor provides beneficial anti-inflammatory properties while reducing fever, pain and opioid consumption. Cumberland supplies Caldolor in two presentations – a vial that requires dilution before use and a pre-mixed bag requiring no dilution. The bag presentation is the first and only FDA-approved ready-to-use injectable ibuprofen.
For more information, including full prescribing and important safety data, visit:
Marketed
Kristalose®
Kristalose® (lactulose) is a prescription laxative administered orally for the treatment of acute and chronic constipation. It is the only branded prescription laxative product that combines the established safety and efficacy of lactulose with the convenience and portability of a pre-measured dose. A unique, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient compliance in the treatment of acute and chronic constipation. Kristalose dissolves quickly in 4 ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups. Kristalose provides a prescription alternative for many patients unable to find relief with over-the-counter laxatives. Additionally, there are no age limitations or length of use restrictions for Kristalose.
For more information, including full prescribing and important safety data, visit:
Marketed
Sancuso®
Sancuso® (granisetron transdermal system) is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment for their cancer. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient’s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (“CINV”). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses. It is the only transdermal patch in its market.
For more information, including full prescribing and important safety data, visit:
Marketed
Vaprisol®
Vaprisol® (conivaptan) is the first and only intravenously administered vasopressin receptor antagonist, a class of pharmaceuticals developed for the treatment of euvolemic and hypervolemic hyponatremia. Vaprisol is indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia by reducing excess water in the body and regulating the water/sodium balance.
Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. It can be associated with a variety of critical care conditions, including congestive heart failure, liver failure, kidney failure, cancer and pneumonia. When partnered with fluid restriction, Vaprisol can provide a positive response in water/sodium balance within 24 hours after beginning therapy.
For more information, including full prescribing and important safety data, visit:
Marketed
Vibativ®
Vibativ® (telavancin) is a patented, FDA-approved injectable antibiotic for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. This life-saving antibiotic features a dual mode of action designed to treat difficult Gram-positive bacterial infections, including MRSA and those that are classified as multidrug-resistant. Additionally, clinical data has demonstrated the superior ability of Vibativ to penetrate lung tissue – an important benefit when treating secondary bacterial infections, such as those seen in COVID-19 patients.
For more information, including full prescribing and important safety data, visit:
